Phase II Open-Label Study to Assess Efficacy and Safety of Lenalidomide in Combination with Cetuximab in KRAS-Mutant Metastatic Colorectal Cancer

• Salvatore Siena ,

  * E-mail: Salvatore.Siena@OspedaleNiguarda.it

  Affiliation Ospedale Niguarda Ca' Granda, Milan, Italy

  ⨯
• Eric Van Cutsem,

  Affiliation University Hospitals Leuven and KU Leuven, Leuven, Belgium

  ⨯
• Mingyu Li,

  Affiliation Celgene Corporation, Summit, New Jersey, United States of America

  ⨯
• Ulf Jungnelius,

  Affiliation Celgene Corporation, Summit, New Jersey, United States of America

  ⨯
• Alfredo Romano,

  Affiliation Celgene Corporation, Summit, New Jersey, United States of America

  ⨯
• Robert Beck,

  Affiliation Celgene Corporation, Summit, New Jersey, United States of America

  ⨯
• Katia Bencardino,

  Affiliation Ospedale Niguarda Ca' Granda, Milan, Italy

  ⨯
• Maria Elena Elez,

  Affiliation Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain

  ⨯
• Hans Prenen,

  Affiliation University Hospitals Leuven and KU Leuven, Leuven, Belgium

  ⨯
• Mireia Sanchis,

  Affiliation Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain

  ⨯
• Andrea Sartore-Bianchi,

  Affiliation Ospedale Niguarda Ca' Granda, Milan, Italy

  ⨯
• Sabine Tejpar,

  Affiliation University Hospitals Leuven and KU Leuven, Leuven, Belgium

  ⨯
• Anita Gandhi,

  Affiliation Celgene Corporation, Summit, New Jersey, United States of America

  ⨯
• Tao Shi,

  Affiliation Celgene Corporation, Summit, New Jersey, United States of America

  ⨯
• Josep Tabernero

  Affiliation Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain

  ⨯